Werewolf Therapeutics Inc

HOWLNASDAQ · USD
0.95USD0.00 (-3.97%)
4310

Werewolf Therapeutics Inc (HOWL) Historical Volatility

HOWL's 30 day historical volatility is 59.44%, in the 10th percentile of readings over the past year. This is a low percentile, meaning Werewolf Therapeutics Inc shares have been calmer than usual. HOWL's 30 day implied volatility sits at 98.25%, with an IV Rank of 24.60%, leaving IV 38.81 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 20, 2026.

Read more

Tracking HOWL historical volatility helps you see how much Werewolf Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, HOWL's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor HOWL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. HOWL's 30 day historical volatility, or HOWL HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing HOWL's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma.

Historical Volatility

HV Percentile
10thHV Percentile
Low

Historical movement is subdued versus the past year. The stock has been unusually quiet.

Historical Volatility (30d)59.44%

HV Percentile10th

Implied Volatility (30d)98.25%

IV Rank24.60%

IV Minus HV+38.81%

As of Nov 20, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 20, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →